Quantum BioPharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Quantum BioPharma has been growing earnings at an average annual rate of 14.5%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 103.2% per year.
Belangrijke informatie
14.5%
Groei van de winst
47.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 103.2% |
| Rendement op eigen vermogen | -80.6% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Quantum BioPharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -7 | 9 | 1 |
| 31 Mar 24 | 0 | -10 | 9 | 2 |
| 31 Dec 23 | 0 | -18 | 13 | 4 |
| 30 Sep 23 | 0 | -23 | 14 | 7 |
| 30 Jun 23 | 0 | -29 | 17 | 8 |
| 31 Mar 23 | 0 | -31 | 19 | 8 |
| 31 Dec 22 | 0 | -27 | 16 | 7 |
| 30 Sep 22 | 0 | -27 | 17 | 5 |
| 30 Jun 22 | 0 | -25 | 16 | 3 |
| 31 Mar 22 | 0 | -30 | 19 | 5 |
| 31 Dec 21 | 0 | -34 | 23 | 6 |
| 30 Sep 21 | 0 | -32 | 22 | 8 |
| 30 Jun 21 | 0 | -39 | 25 | 12 |
| 31 Mar 21 | 0 | -30 | 20 | 9 |
| 31 Dec 20 | 0 | -28 | 18 | 8 |
| 30 Sep 20 | 0 | -36 | 21 | 5 |
| 30 Jun 20 | 0 | -35 | 20 | 2 |
| 31 Mar 20 | 0 | -41 | 24 | 0 |
| 31 Dec 19 | 0 | -34 | 20 | 0 |
| 30 Sep 19 | 0 | -38 | 27 | 0 |
| 30 Jun 19 | 0 | -25 | 22 | 0 |
| 31 Mar 19 | 0 | -16 | 18 | 0 |
| 31 Dec 18 | 0 | -17 | 17 | 0 |
| 30 Sep 18 | 0 | -2 | 7 | 0 |
| 30 Jun 18 | 0 | -7 | 7 | 0 |
| 31 Mar 18 | 0 | -4 | 4 | 0 |
| 31 Dec 17 | 0 | -3 | 3 | 0 |
Kwaliteitswinsten: 0K91 is currently unprofitable.
Groeiende winstmarge: 0K91 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 0K91 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.5% per year.
Versnelling van de groei: Unable to compare 0K91's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 0K91 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rendement op eigen vermogen
Hoge ROE: 0K91 has a negative Return on Equity (-80.64%), as it is currently unprofitable.